Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: A randomized, double-blind, placebo-controlled study

Clinical Drug Investigation

Volumn 30, Issue 7, 2010, Pages 473-482

  Chrysant, Steven G ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Adverse reactions; Antihypertensives; Hydrochlorothiazide; Hypertension; Olmesartan medoxomilhydrochlorothiazide; Olmesartan medoxomil; Therapeutic use

Indexed keywords

HYDROCHLOROTHIAZIDE; OLMESARTAN; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIZZINESS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRAZOLES;

EID: 77953351431     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11536560-000000000-00000     Document Type: Article

References (29)

1. Ostchega Y, Yoon SS, Hughes J, et al. Hypertension awareness, treatment, and control: continued disparities in adults. United States, 2005-2006. NCHS Data Brief 2008 Jan; (3): 1-8
2. Qureshi AI, Suri MF, Kirmani JF, et al. Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000. Med Sci Monit 2005 Sep; 11 (9): CR403-9
3. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 Dec 14; 360 (9349): 1903-1913
4. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: ameta-analysis. Lancet 2001 Oct 20; 358 (9290): 1305-1315
5. Borghi C, Dormi A, D'Addato S, et al. Trends in blood pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart Study. J Hypertens 2004 Sep; 22 (9): 1707-1716 (Pubitemid 39141962)
6. Dusing R. Overcoming barriers to effective blood pressure control in patients with hypertension. Curr Med Res Opin 2006 Aug; 22 (8): 1545-1553
7. Mancia G, Seravalle G, Grassi G. Tolerability and treatment compliance with angiotensin II receptor antagonists. Am J Hypertens 2003 Dec; 16 (12): 1066-1073
8. Ambrosioni E, Leonetti G, Pessina AC, et al. Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy. J Hypertens 2000 Nov; 18 (11): 1691-1699
9. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003 May 21; 289 (19): 2560-2572
10. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000 Feb 19; 355 (9204): 637-645
11. Reid JL. New therapeutic agents for hypertension. Br J Clin Pharmacol 1996; 42: 37-41
12. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998 Jul-Aug; 20 (4): 671-681
13. Ross SD, Akhras KS, Zhang S, et al. Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis. Pharmacotherapy 2001 Aug; 21 (8): 940-953
14. Kochar M, Guthrie R, Triscari J, et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999 Aug; 12 (8 Pt 1): 797-805
15. Manolis AJ, Grossman E, Jelakovic B, et al. Effects of losartan and candesartan monotherapy and losartan/ hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clin Ther 2000 Oct; 22 (10): 1186-1203
16. White WB, Punzi HA, Murwin D, et al. Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25mg once daily for the treatment of hypertension. J Clin Hypertens (Greenwich) 2006 Sep; 8 (9): 626-633
17. Oparil S, Chrysant SG, Kereiakes D, et al. Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients. J Clin Hypertens (Greenwich) 2008 Dec; 10 (12): 911-921
18. Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999 Jul; 21 (1): 23-33 (Pubitemid 29355511)
19. Ram CV. Antihypertensive drugs: an overview. Am J Cardiovasc Drugs 2002; 2 (2): 77-89
20. Barrios V, Boccanelli A, Ewald S, et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. Clin Drug Investig 2007; 27 (8): 545-558
21. Chrysant SG, Weber MA, Wang AC, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004 Mar; 17 (3): 252-259
22. Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest 2003; 23 (7): 419-430
23. Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008 Apr; 30 (4): 587-604
24. Forman DE, Lipsitz LA. Syncope in the elderly. Cardiol Clin 1997 May; 15 (2): 295-311
25. Kapoor WN. Syncope in older persons. J Am Geriatr Soc 1994 Apr; 42 (4): 426-436
26. Izzo Jr JL, Neutel JM, Silfani T, et al. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J Clin Hypertens (Greenwich) 2007 Jan; 9 (1): 36-44
27. Goncalves CB, Moreira LB, GusM, et al. Adverse events of blood-pressure-lowering drugs: evidence of high incidence in a clinical setting. Eur J Clin Pharmacol 2007 Oct; 63 (10): 973-978
28. Ofili EO. Dispelling the myth of "aggressive" antihypertensive therapy. J Clin Hypertens (Greenwich) 2006 Jan; 8 (1 Suppl. 1): 4-11
29. Neutel JM, Smith DH. Improving patient compliance: a major goal in the management of hypertension. J Clin Hypertens (Greenwich) 2003 Mar-Apr; 5 (2): 127-132